Discovery of a first-in-class orally available HBV cccDNA inhibitor.
Wang L, Zhu Q, Zhang JD, Zhang Y, Ni X, Xiang K, Jiang J, Li B, Yu Y, Hu H, Zhang M, Wu W, Zeng J, Yan Z, Dai J, Sun K, Zhang X, Chen D, Feng S, Sach-Peltason L, Young JAT, Gao L.
Wang L, et al.
J Hepatol. 2023 Apr;78(4):742-753. doi: 10.1016/j.jhep.2022.12.014. Epub 2022 Dec 30.
J Hepatol. 2023.
PMID: 36587899